SETD2 and cancer: A high frequency of SETD2 mutations was recently disclosed in several cancers, of which clear cell renal cell carcinoma (ccRCC) shows the highest SETD2 mutation rate (Dalgliesh et al., 2010; Varela et al., 2011).